Overview

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Status:
Completed
Trial end date:
2013-03-29
Target enrollment:
Participant gender:
Summary
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Zanamivir